JP2023542348A5 - - Google Patents

Info

Publication number
JP2023542348A5
JP2023542348A5 JP2023518205A JP2023518205A JP2023542348A5 JP 2023542348 A5 JP2023542348 A5 JP 2023542348A5 JP 2023518205 A JP2023518205 A JP 2023518205A JP 2023518205 A JP2023518205 A JP 2023518205A JP 2023542348 A5 JP2023542348 A5 JP 2023542348A5
Authority
JP
Japan
Prior art keywords
gene
disrupted
population
cells
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023518205A
Other languages
English (en)
Japanese (ja)
Other versions
JP7899165B2 (ja
JP2023542348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/058704 external-priority patent/WO2022064428A1/en
Publication of JP2023542348A publication Critical patent/JP2023542348A/ja
Publication of JP2023542348A5 publication Critical patent/JP2023542348A5/ja
Application granted granted Critical
Publication of JP7899165B2 publication Critical patent/JP7899165B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023518205A 2020-09-23 2021-09-23 Regnase-1及び/又はTGFBRIIを破壊した遺伝子操作されたT細胞は機能性及び持続性を改善させた Active JP7899165B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063082357P 2020-09-23 2020-09-23
US63/082,357 2020-09-23
US202063124429P 2020-12-11 2020-12-11
US63/124,429 2020-12-11
US202163225673P 2021-07-26 2021-07-26
US63/225,673 2021-07-26
PCT/IB2021/058704 WO2022064428A1 (en) 2020-09-23 2021-09-23 Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence

Publications (3)

Publication Number Publication Date
JP2023542348A JP2023542348A (ja) 2023-10-06
JP2023542348A5 true JP2023542348A5 (cg-RX-API-DMAC7.html) 2024-09-24
JP7899165B2 JP7899165B2 (ja) 2026-08-03

Family

ID=78080385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518205A Active JP7899165B2 (ja) 2020-09-23 2021-09-23 Regnase-1及び/又はTGFBRIIを破壊した遺伝子操作されたT細胞は機能性及び持続性を改善させた

Country Status (12)

Country Link
US (6) US20220090012A1 (cg-RX-API-DMAC7.html)
EP (2) EP4176048B1 (cg-RX-API-DMAC7.html)
JP (1) JP7899165B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230074515A (cg-RX-API-DMAC7.html)
CN (1) CN116322716A (cg-RX-API-DMAC7.html)
AU (1) AU2021347907A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192280A1 (cg-RX-API-DMAC7.html)
ES (1) ES2993268T3 (cg-RX-API-DMAC7.html)
IL (1) IL301012A (cg-RX-API-DMAC7.html)
MX (1) MX2023003365A (cg-RX-API-DMAC7.html)
TW (1) TW202229545A (cg-RX-API-DMAC7.html)
WO (1) WO2022064428A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108452WA (en) * 2019-02-04 2021-09-29 Ksq Therapeutics Inc Combination gene targets for improved immunotherapy
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
MX2022015586A (es) 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
WO2023007373A1 (en) * 2021-07-26 2023-02-02 Crispr Therapeutics Ag Methods for manufacturing genetically engineered car-t cells
WO2023084399A1 (en) 2021-11-09 2023-05-19 Crispr Therapeutics Ag Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
US20230346836A1 (en) 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
US20230331841A1 (en) 2022-03-23 2023-10-19 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2023180968A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
CN119451992A (zh) 2022-06-29 2025-02-14 克里斯珀医疗股份公司 靶向gpc-3的嵌合抗原受体和表达其的免疫细胞用于治疗用途
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
EP4587477A2 (en) * 2022-09-14 2025-07-23 Ohio State Innovation Foundation Methods for reprograming exhausted t cells and boosting immune checkpoint blockade therapy for cancer
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
US20240115703A1 (en) * 2022-10-10 2024-04-11 Crispr Therapeutics Ag Genetically engineered anti-cd19 car-t cells for use in treating b-cell malignancies
WO2024229098A2 (en) * 2023-05-01 2024-11-07 Wisconsin Alumni Research Foundation Methods and systems for predicting potent t cell products
US12500832B2 (en) 2023-08-28 2025-12-16 Ciena Corporation Establishing and advertising co-routed bidirectional paths across multiple domains
WO2025126049A2 (en) 2023-12-11 2025-06-19 Crispr Therapeutics Ag Multiplex gene editing
IL330230A (en) * 2023-12-20 2026-08-01 Intellia Therapeutics Inc Engineered T cells
CN117844811A (zh) * 2024-03-08 2024-04-09 上海恒润达生生物科技股份有限公司 靶向敲除CD70基因的sgRNA组合物及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JPWO2010098429A1 (ja) 2009-02-27 2012-09-06 国立大学法人大阪大学 免疫アジュバント組成物、及びその利用
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US20160145348A1 (en) 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US20180112198A1 (en) 2015-04-15 2018-04-26 Saint Louis University Tumor suppression by mcpip1
JP2017002928A (ja) 2015-06-05 2017-01-05 株式会社デンソー 複数軸駆動用アクチュエータ
WO2017002928A1 (ja) 2015-06-30 2017-01-05 岸本 忠三 新規な肺疾患治療剤および/またはそのスクリーニング方法
EP4339287A3 (en) * 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11352631B2 (en) * 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11166985B2 (en) * 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CA3081456A1 (en) * 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
CA3093919A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3765094A4 (en) * 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
WO2019235581A1 (ja) 2018-06-06 2019-12-12 国立大学法人大阪大学 Regnase-1が関与する疾患の治療および/または予防方法
WO2020032160A1 (ja) 2018-08-09 2020-02-13 国立大学法人大阪大学 炎症性腸疾患治療薬およびそのスクリーニング方法
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
SG11202103832SA (en) 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
KR20210116526A (ko) * 2019-01-16 2021-09-27 빔 테라퓨틱스, 인크. 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
CA3138633A1 (en) * 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
JP6957572B2 (ja) 2019-09-19 2021-11-02 フランスベッド株式会社 ベッド装置
AU2020382219A1 (en) 2019-11-13 2022-05-12 Crispr Therapeutics Ag Manufacturing process for making T cells expressing chimeric antigen receptors

Similar Documents

Publication Publication Date Title
US11999773B2 (en) Anti-BCMA chimeric antigen receptors
CA3133333A1 (en) Chimeric receptors and methods of use thereof
KR20230024984A (ko) Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포
CN113614108A (zh) G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
AU2023206126B2 (en) TGF-β receptors and methods of use
JP2021522820A5 (cg-RX-API-DMAC7.html)
AU2020315796A1 (en) Fusion polypeptide for immunotherapy
WO2018108106A1 (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
IL264144B1 (en) Antibody 18a2 against claudin and its use
JP2019525771A5 (cg-RX-API-DMAC7.html)
TWI915404B (zh) 用於治療egfr陽性癌症之組合物及方法
JP2022512882A5 (cg-RX-API-DMAC7.html)
RU2017121892A (ru) Клетка
TW202229358A (zh) 前列腺癌嵌合抗原受體
WO2020172641A1 (en) Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
IL304857A (en) Preparations and methods for treating HER2 POSITIVE cancer
US20220185882A1 (en) Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same
CN114450397A (zh) 用于改善免疫疗法的细胞及其用途
CA3154389A1 (en) Antigen recognizing receptors targeting cd371 and uses thereof
TW202309294A (zh) 病毒載體生產系統
JP2024527537A5 (cg-RX-API-DMAC7.html)
TW202242117A (zh) 包含多順反子表現卡匣之重組載體及其使用方法
KR20230090367A (ko) 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
IL319598A (en) Anti-ROR1 chimeric antigen receptors, CAR-NK cells and related methods
JP2022550120A5 (cg-RX-API-DMAC7.html)